FDA clears Immune-Onc to start trial of Keytruda combo in solid-tumor patients

Written By Lara Wilson

The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.

Lara Wilson
Previous

Most VC Funded Women-Led Life Sciences Companies in the Bay Area
Next

LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies